Keros doses first patient in Phase 2 rinvatercept trial in DMD; initial data expected in H1 2027

Keros Therapeutics, Inc.

First patient dosed in open-label, multi-cohort Phase 2 basket trial (NCT07704099) of rinvatercept in late-ambulatory and early non-ambulatory Duchenne muscular dystrophy patients.
Primary objective is safety and tolerability; key secondary objectives include pharmacokinetics, anti-drug antibodies, body composition and skeletal muscle, motor, cardiac and pulmonary function.
Company expects initial data from the trial in the first half of 2027.
CEO Jasbir Seehra said rinvatercept is designed to modulate key regulators of muscle and bone biology, advancing Keros' neuromuscular strategy.
Gina O'Grady of Starship Children's Hospital said DMD still places a significant burden on patients and the need for additional options remains high.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.